journal
https://read.qxmd.com/read/37854341/serum-linc00152-and-uca1-in-hcv-induced-hepatocellular-carcinoma-clinical-significance-and-prognostic-value
#1
JOURNAL ARTICLE
Somaia Shehab-Eldeen, Abdallah Essa, Eman Salah Arafat, Asmaa Shaaban Sleem, Amal Abdelrasoul Alhosary, Ehab Darwish, Ali Essa, Omar Ahmed Al-Omair, Emad Ali Al-Khoufi, Abdulrhman Khaled Al Abdulqader, Ali Nada
BACKGROUND: Despite significant advancements in the molecular characterization of hepatocellular carcinoma (HCC), no oncogene addiction has been discovered. Long noncoding RNAs (lncRNAs) have a lot of promise as cancer biomarkers. LINC00152 and UCA1 have shown potential as diagnostic, prognostic, and therapeutic targets for human cancers. AIM: To investigate the diagnostic and prognostic potential of serum LINC00152 and UCA1 in hepatocellular carcinoma (HCC). METHODS: The expression levels of LINC00152 and UCA1 in blood samples from 120 patients (60 with HCC, 60 with liver cirrhosis) and 40 healthy subjects were assessed using real-time qRT-PCR...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/37814674/treatment-persistence-of-apremilast-among-patients-with-psoriatic-arthritis
#2
JOURNAL ARTICLE
Amir Haddad, Nili Stein, Idit Lavi, Lisa Shynkar, Irina Bergman, Ilan Feldhamer, Arnon Dov Cohen, Walid Saliba, Devy Zisman
INTRODUCTION: Persistence in drug therapy reflects treatment effectiveness and tolerability. We aim to estimate the persistence of apremilast prescribed to patients with psoriatic arthritis (PsA) and to identify characteristics associated with treatment discontinuation in a real-world setting. METHODS: Patients with PsA treated with apremilast from January 2016 were identified from a large health database and followed until medication stop date (using 3-months grace period), death or the end of observation period (June 2021)...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/37767463/molecular-biology-mechanisms-and-emerging-therapeutics-of-triple-negative-breast-cancer
#3
REVIEW
Zhiying Zhang, Rui Zhang, Donghai Li
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is conventionally characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), accounting for approximately 15-20% of all breast cancers. Compared to other molecular phenotypes, TNBC is typically associated with high malignancy and poor prognosis. Cytotoxic agents have been the mainstay of treatment for the past few decades due to the lack of definitive targets and limited therapeutic interventions...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/37223116/effectiveness-of-rcts-pooling-evidence-on-mesenchymal-stem-cell-msc-therapeutic-applications-during-covid-19-epidemic-a-systematic-review
#4
REVIEW
Usha Rani Kandula, Addisu Dabi Wake
BACKGROUND: Global pandemic identified as coronavirus disease 2019 (COVID-19) has resulted in a variety of clinical symptoms, from asymptomatic carriers to those with severe acute respiratory distress syndrome (SARS) and moderate upper respiratory tract symptoms (URTS). This systematic review aimed to determine effectiveness of stem cell (SC) applications among COVID-19 patients. METHODS: Multiple databases of PubMed, EMBASE, Science Direct, Google Scholar, Scopus, Web of Science, and Cochrane Library were used...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/37213261/new-uracil-analog-with-exocyclic-methylidene-group-can-reverse-resistance-to-taxol-in-mcf-7-cancer-cells
#5
JOURNAL ARTICLE
Angelika Długosz-Pokorska, Renata Perlikowska, Tomasz Janecki, Anna Janecka
INTRODUCTION: Taxol (Tx), a microtubule-stabilizing drug, has been widely used as a chemotherapeutic in several types of cancer. However, the development of resistance limited its application. One of the strategies used to prevent the emergence of drug resistance is combination treatment, involving at least two drugs. The aim of the current study was to assess if a new uracil analog, 3- p -bromophenyl-1-ethyl-5-methylidenedihydrouracil (U-359) can prevent the development of Tx resistance in breast cancer cells...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/37163178/treating-alpelisib-induced-hyperinsulinemia-in-patients-with-advanced-breast-cancer-a-real-life-experience
#6
Ruth Percik, Cecilie Oedegaard Smith, Anca Leibovici, Ayelet Shai
PIK3CA activating mutations are found in 40% of advanced breast cancer and are associated with worse prognosis. PI3K blockage is associated with insulin resistance, leading to hyperglycemia and hyperinsulinemia. Alpelisib is the first PI3K inhibitor used in cancer treatment. Laboratory evidence indicated that alpelisib-induced hyperinsulinemia offsets the drug's efficacy, but insulin levels were not tested in the clinical trials that evaluated alpelisib for breast cancer. Hyperglycemia could also interfere with anti-tumor effects of PI3K inhibitors by inducing Immune tolerance and altered mitochondrial metabolism...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/37101561/hypereosinophilic-dermatitis-successful-treatment-with-dupilumab
#7
Chenyu Wu, Jianzhong Zhang, Yan Zhao
Hypereosinophilic dermatitis (HED) is a subtype of hypereosinophilic syndrome. HED is characterized by eosinophilic granulocytes increased in peripheral blood and bone marrow and infiltrated in skin. The clinical manifestations of HED are diffussed by erythema, papule and maculopapule with severe itching. The etiology of HED is unknown. At present, in addition to HED with FIP1L1-PDGFRA fusion gene positive, whose treatment is tyrosine kinase inhibitor, other types of HED first-line treatment are oral glucocorticoids, supplemented by antihistamines and immunosuppressants...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36969332/why-and-how-should-ethiopia-establish-a-stem-cell-transplant-service-a-review-article
#8
REVIEW
Sintayehu Mekonnen, Hawi Farris
Ethiopia is attempting to reduce cancer-related morbidity and mortality through a strategic national cancer control plan but according to Globocan 2020, hematologic malignancies particularly leukemia and non-Hodgkin's lymphoma rank among the top five leading causes of new cancer incidence and cause of death among all age groups in both sexes. Hematopoietic stem-cell transplantation (HSCT) is an advanced treatment modality that makes the only effective treatment for cancer and non-cancer-related hematologic diseases unresponsive to conventional therapy...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36969331/critical-response-does-the-mutation-of-cancer-driver-genes-idh1-2-and-cd204-influence-cancer-metabolism-and-tumor-associated-macrophage-recruitment-in-tumor-microenvironment-letter
#9
JOURNAL ARTICLE
Novaria Sari Dewi Panjaitan, Sarwo Handayani, Rita Marleta Dewi
No abstract text is available yet for this article.
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36969330/elevated-serum-vinculin-in-patients-with-hbv-hcv-associated-liver-cirrhosis-and-hepatocellular-carcinoma-a-pilot-study
#10
JOURNAL ARTICLE
Abdallah Essa, Enas Said Essa, Sara Mahmoud El-Deeb, Hossam Eldin Mostafa Seleem, Muthana Al Sahlawi, Omar Ahmed Al-Omair, Somaia Shehab-Eldeen
BACKGROUND: The stiffness of the extracellular matrix (ECM) controls many cellular processes, such as migration and differentiation. Cells detect stiffness through adhesion structures termed focal adhesions (FAs). Vinculin, an actin-binding FA protein, plays a pivotal role in FA-mediated mechanotransduction. AIM: This study aimed to explore the role of vinculin in the development of HBV/HCV-induced hepatocellular carcinoma (HCC). METHODS: Vinculin levels in a total number of 100 serum samples from patients with HBV/HCV-induced liver cirrhosis and HCC, as well as healthy controls, were analyzed using an enzyme-linked immunosorbent assay (ELISA)...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36969329/demonstration-of-safety-in-wild-type-mice-of-npfoxf1-a-novel-nanoparticle-based-gene-therapy-for-alveolar-capillary-dysplasia-with-misaligned-pulmonary-veins
#11
JOURNAL ARTICLE
Fatemeh Kohram, Zicheng Deng, Yufang Zhang, Abid A Al Reza, Enhong Li, Olena A Kolesnichenko, Samriddhi Shukla, Vladimir Ustiyan, Jose Gomez-Arroyo, Anusha Acharya, Donglu Shi, Vladimir V Kalinichenko, Alan P Kenny
INTRODUCTION: Alveolar Capillary Dysplasia with Misaligned Pulmonary Veins (ACDMPV) is a fatal congenital disease resulting from a pulmonary vascular endothelial deficiency of FOXF1, producing abnormal morphogenesis of alveolar capillaries, malpositioned pulmonary veins and disordered development of lung lobes. Affected neonates suffer from cyanosis, severe breathing insufficiency, pulmonary hypertension, and death typically within days to weeks after birth. Currently, no treatment exists for ACDMPV, although recent murine research in the Kalinichenko lab demonstrates nanoparticle delivery improves survival and reconstitutes normal alveolar-capillary architecture...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36778762/the-cancer-driver-genes-idh1-and-idh2-and-cd204-in-who-grade-4-astrocytoma-crosstalk-between-cancer-metabolism-and-tumour-associated-macrophage-recruitment-in-tumour-microenvironment
#12
JOURNAL ARTICLE
Maher Kurdi, Nasser Mulla, Yousef Katib, Taghreed Alsinani, Sahar Hakamy, Bassam Mj Addas, Husam Malibary, Taher F Halawa, Marwa S Farhan, Eyad Faizo, Saleh Baeesa
PURPOSE: IDH1 and IDH2 are hotspot mutations commonly identified in WHO-grade 4 astrocytomas. Their association with TAMs has never been investigated. We aim to explore the crosstalk between the IDH1/2 mutation metabolic effect and TAMs in tumour microenvironment and how this relationship affects the tumour recurrence. PATIENTS AND METHODS: The study included 20 samples of patients with WHO-grade 4 astrocytoma. The alteration hotspot in codon IDH1R132 and IDH2R172 was examined using direct sequencing...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36721867/preliminary-assessment-of-safety-and-tolerability-of-avacopan-during-the-early-access-program-for-anca-associated-vasculitis
#13
JOURNAL ARTICLE
Jolijn R van Leeuwen, Tamara Popov, Achim Obergfell, Ton J Rabelink, Y K Onno Teng
No abstract text is available yet for this article.
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36698375/significance-of-interleukin-23-in-systemic-lupus-patients-relation-to-disease-activity-and-damage-indices
#14
JOURNAL ARTICLE
Maysa M Haroon, Gehan A Hegazy, Mohammed A Hassanien, Olfat Shaker, Wafaa H Hussein
BACKGROUND: Dysregulation of both cellular and humoral immune responses is central in systemic lupus erythematosus (SLE) pathogenetic mechanisms. Proinflammatory cytokines, such as interleukin 23 (IL23), and their roles in promoting such dysregulation have recently been highly considered. This research compared IL23 serum levels in 85 Egyptian SLE patients and 85 healthy controls. Then, IL23 level was correlated to various SLE disease parameters, disease activity, and damage indices. RESULTS: IL23 serum levels were significantly elevated in SLE patients versus healthy individuals...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36440060/adherence-to-subcutaneous-anti-tumour-necrosis-factor-treatment-in-a-cohort-of-patients-with-rheumatoid-arthritis-before-and-after-the-implementation-of-a-comprehensive-care-model
#15
JOURNAL ARTICLE
Pedro Santos-Moreno, Guillermo Sánchez-Vanegas, Angélica Monterrosa-Blanco, Gabriel-Santiago Rodríguez-Vargas, Manuel Rivero, Pedro Rodriguez, Omar-Javier Calixto, Adriana Rojas-Villarraga, Carlos Alberto Castro
PURPOSE: To assess, in a cohort of patients with rheumatoid arthritis (RA) treated with subcutaneous antitumor necrosis factor drugs (anti-TNFs), the levels of treatment adherence before and after implementing a comprehensive care model (CCM). PATIENTS AND METHODS: An observational study including RA patients under treatment with subcutaneous anti-TNFs (adalimumab, etanercept, and golimumab) selected at convenience was performed; a sample size of 125 patients was calculated...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/36281333/tnf-inhibitors-exert-a-hidden-beneficial-effect-in-the-cardiovascular-lipoprotein-profile-of-ra-patients
#16
JOURNAL ARTICLE
Jaime Calvo Alén, Bernardo Alio Lavin-Gomez, Elena Aurrecoechea, Armando Raul Guerra Ruiz, Víctor Martínez Taboada, Juan Gómez Gerique
Purpose: A high cardiovascular risk has been described in patients with rheumatoid arthritis (RA); the effects of different biological agents have also been described in these patients. The aim of the present study is to examine the effects of tumor necrosis factor inhibitors (TNFi) in the lipoprotein profile of RA patients using a broad laboratory assessment including a large number of non-routine tests. Patients and Methods: RA patients treated with and without TNFi (70 patients in each group) were cross-sectionally compared regarding a broad spectrum of lipoprotein parameters including serum levels of total and HDL, LDL and VLDL cholesterol triglycerides, lipoprotein A (LpA), apolipoprotein A1 (Apo A), B100 (Apo B) and paroxonase...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/36225325/phage-therapy-a-different-approach-to-fight-bacterial-infections
#17
REVIEW
Zigale Hibstu, Habtamu Belew, Yibeltal Akelew, Hylemariam Mihiretie Mengist
Phage therapy is one of the alternatives to treat infections caused by both antibiotic-sensitive and antibiotic-resistant bacteria, with no or low toxicity to patients. It was started a century ago, although rapidly growing bacterial antimicrobial resistance, resulting in high levels of morbidity, mortality, and financial cost, has initiated the revival of phage therapy. It involves the use of live lytic, bioengineered, phage-encoded biological products, in combination with chemical antibiotics to treat bacterial infections...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/36225324/biosimilars-science-implications-and-potential-outlooks-in-the-middle-east-and-africa
#18
REVIEW
Radwa Ahmed Batran, Mai Elmoshneb, Ahmed Salah Hussein, Omar M Hussien, Fady Adel, Reham Elgarhy, Mosaad I Morsi
Biosimilars are biological products that efficiently replicate the function of the originator products. They have changed the prognosis of millions of patients with many serious conditions. The main engine beyond their development is to bring competition into the marketplace, accordingly further the healthcare systems' sustainability. Furthermore, by lowering financial obstacles to biological treatments, biosimilars play a critical role in budgetary redistribution and, hence, promote better allocation of scarce healthcare resources...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/36213816/emerging-therapies-for-huntington-s-disease-focus-on-n-terminal-huntingtin-and-huntingtin-exon-1
#19
REVIEW
M Leontien van der Bent, Melvin M Evers, Astrid Vallès
Huntington's disease is a devastating heritable neurodegenerative disorder that is caused by the presence of a trinucleotide CAG repeat expansion in the Huntingtin gene, leading to a polyglutamine tract in the protein. Various mechanisms lead to the production of N-terminal Huntingtin protein fragments, which are reportedly more toxic than the full-length protein. In this review, we summarize the current knowledge on the production and toxicity of N-terminal Huntingtin protein fragments. Further, we expand on various therapeutic strategies targeting N-terminal Huntingtin on the protein, RNA and DNA level...
2022: Biologics: Targets & Therapy
https://read.qxmd.com/read/36118798/a-review-on-inflammatory-bowel-diseases-recent-molecular-pathophysiology-advances
#20
REVIEW
Maheeba Abdulla, Nafeesa Mohammed
Inflammatory bowel diseases are considered immune disorders with a complex genetic architecture involving constantly changing endogenous and exogenous factors. The rapid evolution of genomic technologies and the emergence of newly discovered molecular actors are compelling the research community to reevaluate the knowledge and molecular processes. The human intestinal tract contains intestinal human microbiota consisting of commensal, pathogenic, and symbiotic strains leading to immune responses that can contribute and lead to both systemic and intestinal disorders including IBD...
2022: Biologics: Targets & Therapy
journal
journal
41818
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.